Xeris Biopharma Holdings, Inc. 4

Director Nerissa Kreher received 33,582 RSU shares and 37,910 stock options of Xeris Biopharma Holdings, Inc. as part of routine equity compensation on July 1, 2026.

On July 1, 2026, Director Nerissa Kreher of Xeris Biopharma Holdings, Inc. received an equity compensation package consisting of 33,582 shares of common stock in the form of restricted stock units and 37,910 stock options under the company’s 2018 Stock Option and Incentive Plan, with both the RSUs and options vesting in equal annual installments over three years contingent on continued Board service; following these grants, she holds 37,910 shares of common stock directly, reflecting a routine director compensation award rather than an open‑market purchase or sale. Because no transaction price is indicated and no market price data is provided, the dollar value of these grants and her post‑transaction holdings cannot be reliably estimated from the filing alone.

Filing Facts

CIK

1867096

Ticker

XERS

Form

4

Source Type

sec

Accession

0001741850-26-000002

Alert Tier

5